Acesis Biomed

Acesis BioMed is a preclinical-stage biotech targeting the multi-billion dollar male hypogonadism market with an oral peptide designed to stimulate endogenous testosterone production, offering a potential alternative to current testosterone replacement therapies (TRT). Founded on foundational IP from Dr. Vassilios Papadopoulos's research on mitochondrial cholesterol transport, the company has secured $5.8M in funding and employs a capital-efficient virtual model. Its strategy involves advancing its lead candidate to First-in-Human trials before expanding the platform into related metabolic comorbidities like type 2 diabetes and NAFLD.

Proprietary oral peptide platform targeting mitochondrial cholesterol transport to stimulate endogenous testosterone production.

Acesis competes in the male hypogonadism market dominated by established testosterone replacement therapies (gels, injections, implants) from companies like AbbVie, Endo, and Lilly. Its primary differentiation is the oral, non-steroidal mechanism aiming to stimulate natural production, potentially offering a safer profile. It also faces competition from other novel oral therapies in development.